British Biotech merges with RiboTargets
Following talks that began in January, British Biotech (matrix metalloproteinase inhibitors, MMPIs) has agreed to merge with RiboTargets (anti-infectives and oncology drugs). RiboTargets' CEO Simon Sturge becomes CEO of the new biotech company, which will be 50.01% owned by the shareholders of BB, and 49.99% by RiboTargets.
- Drug Discovery Tools
- Intra-Biotech Deal
- Partial Acquisition
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com